

DLS-EXTENDED CARE FACILITIES
ANTIMICROBIAL SUSCEPTIBILITY PROFILES (January 01 – June 30, 2007)
(All sources)

GRAM NEGATIVE SUSCEPTIBILITIES (Percent Susceptible)

	Enterobacter aerogenes	Enterobacter cloacae	E. coli	E. coli ESBL	Klebsiella pneumoniae	Klebsiella pneumoniae ESBL	Pseudomonas aeruginosa	Serratia marcescens
Amoxicillin/CA	--	--	69	--	93	--	--	--
Ampicillin	--	--	42	--	--	--	--	--
Cefuroxime	--	--	72	--	93	--	--	--
Ceftriaxone	0*	100*	95	--	100	--	22	100*
Cephalothin	--	--	44	--	85	--	--	--
Ciprofloxacin	100*	100*	64	0*	89	N/A	53	89*
Gentamicin	100*	100*	84	67*	100	N/A	100	100*
Minocycline	0*	25*	64	0*	78	N/A	--	89*
Nalidixic Acid	100*	75*	55	0*	74	N/A	--	22*
Nitrofurantoin	67*	50*	94	100*	56	N/A	--	--
Norfloxacin (u)	100*	100*	64	0*	89	N/A	53	89*
Tobramycin	100*	100*	92	67*	100	N/A	100	100*
Levofloxacin	100*	100*	64	0*	89	N/A	53	89*
Trimeth-Sulfa	100*	100*	68	33*	85	N/A	--	100*
Total Isolates	3	4	79		27		32	9

GRAM POSITIVE AND *H. influenzae* SUSCEPTIBILITIES (Percent Susceptible)

	Staph. aureus	Staph. coag neg	Enterococcus	Haemophilus influenzae
Ampicillin	--	--	81	100*
Ceftriaxone	--	--	--	100*
Cefazolin	37	82	--	--
Cefuroxime	--	--	--	100*
Clindamycin **	43	64	--	--
Erythromycin	13	55	--	--
Gentamicin	83	73	--	--
Levofloxacin	13	64	--	--
Meropenem	--	--	--	100*
Moxifloxacin	57	70	--	100*
Nitrofurantoin (u)	100	100	81	--
Oxacillin	37	82	--	--
Penicillin	10	64	--	--
Rifampin ***	93	100	--	--
Tetracycline	73	73	44	--
Trimeth-Sulfa	97	91	--	100*
Vancomycin	100	100	100	--
Total Isolates	30	11	16	1

* For total isolates of less than 10, the susceptibility percentage may not be clinically significant.

** Clindamycin results have been verified by induction test.

*** Rifampin should not be used alone for treatment of staph infection.